Rapport Therapeutics: director John Maraganore bought 9,411 shares

What happened The Form 4 reports that John Maraganore, a director, purchased 8,239 shares at $26.38 for $217,344 and 1,172 shares at $26.92 for $31,547 on Oct 22, 2026, for a total of 9,411 shares and $248,891.

Key details

• Transaction date: Oct 22, 2026. Report filed Oct 22, 2026.
• Prices reported: $26.38 (for 8,239 shares) and $26.92 (for 1,172 shares); filing footnotes state the reported prices are weighted averages. Footnote 1: purchases ranged from $25.81 to $26.73. Footnote 2: purchases ranged from $26.81 to $26.98. The reporting person offers to provide per-price breakouts on request.
• Shares owned after the transaction: not stated in the provided summary of the Form 4.
• Late filing: no late filing is indicated (transaction date and filing date are the same).

Why it may matter

• This transaction is reported as open market purchases (code P). It is not reported as an option exercise, gift, award, or tax withholding.
• A filing does not show why the insider traded or why the company acted.